Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest Doxil Stories

2013-01-22 08:30:06

NEW BRUNSWICK, N.J., Jan. 22, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $17.6 billion for the fourth quarter of 2012, an increase of 8.0% as compared to the fourth quarter of 2011. Operational results increased 9.3% and the negative impact of currency was 1.3%. Domestic sales increased 6.8%, while international sales increased 8.9%, reflecting operational growth of 11.2% and a negative currency impact of 2.3%. Sales for the fourth quarter of 2012 included...

2012-10-22 07:29:47

SEATTLE, Oct. 22, 2012 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. announced today the initiation of a randomized, placebo-controlled, Phase 2 trial evaluating VTX-2337 in combination with Doxil(®) (pegylated liposomal doxorubicin) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior platinum-based chemotherapy. The trial will investigate whether combining VTX-2337 with Doxil(®), a standard second-line...

2012-10-16 07:26:48

NEW BRUNSWICK, N.J., Oct. 16, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $17.1 billion for the third quarter of 2012, an increase of 6.5% as compared to the third quarter of 2011. Operational results increased 10.8% and the negative impact of currency was 4.3%. Domestic sales increased 13.4%. International sales increased 1.4%, reflecting operational growth of 8.9% and a negative currency impact of 7.5%. Sales included the impact of the recently completed...

FDA Rushes To Fix Shortage Of Cancer Drugs
2012-02-21 15:03:31

The Food and Drug Administration (FDA) announced plans on Tuesday to help resupply the U.S. with two leading cancer drugs. The agency said they will address shortages of two leading cancer drugs by allowing one of them to be imported from abroard, and rush approval for a new manufacturer to make the second. "We're not out of the woods," Dr Sandra L Kweder of the Food and Drug Administration's drug center told the New York Times. "But these two particular shortages have been very, very...

2009-09-10 16:27:00

HORSHAM, Pa., Sept. 10 /PRNewswire/ -- Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer. Centocor Ortho Biotech is evaluating the FDA's letter and will respond to the agency as quickly...

2009-07-15 16:22:00

HORSHAM, Pa., July 15 /PRNewswire/ -- Based on the data presented today, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended that the combination of DOXIL(R) (doxorubicin HCI liposome injection) and docetaxel did not provide a sufficient benefit-risk profile for the treatment of women with locally advanced or metastatic breast cancer. Women with locally advanced and metastatic breast cancer who have received prior anthracycline treatment...

2008-12-14 11:19:00

SAN ANTONIO, Dec. 14 /PRNewswire/ -- Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time to disease progression (TTP) and overall response rates after receiving a combination of DOXIL(R) (doxorubicin HCl liposome injection) and docetaxel as compared to docetaxel alone. Results from this randomized, parallel-group, open-label, multi-center...

2008-09-09 09:00:09

Ortho Biotech Products, a biopharmaceutical company, has submitted a supplemental new drug application to the FDA for the combination of Doxil and Taxotere for the treatment of women with advanced breast cancer who have received prior anthracycline treatment. The application to the FDA follows the completion of a randomized, parallel-group, open-label, multicenter Phase III clinical trial that evaluated time to progression (TTP) of the disease with combination versus monotherapy docetaxel...

2008-09-08 09:00:08

BRIDGEWATER, N.J., Sept. 8 /PRNewswire/ -- Ortho Biotech Products, L.P. today announced that the Company has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the combination of DOXIL(R) (doxorubicin HCl liposome injection) and Taxotere(R) (docetaxel)* for the treatment of women with advanced breast cancer who have received prior anthracycline treatment. The application to the FDA follows the completion of a randomized, parallel-group,...

2008-08-13 09:01:15

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a four-drug combination study with REVLIMID(R) (lenalidomide), VELCADE(R) (bortezomib) for Injection, DOXIL(R) (doxorubicin HCl liposome injection) and dexamethasone for the treatment of multiple myeloma in patients who are previously untreated. The University of Michigan, one of fifteen MMRC member institutions, will evaluate the safety and efficacy of the drug combination in patients who have not received...